EU steps up its fight against drug-resistant bacteria
A survey published by the European Commission today (November 15) reveals a decrease in antibiotic use in humans since 2009 and growing public awareness that antibiotics do not kill viruses.
However, this positive news is overshadowed by data released in parallel by the European Center for Disease Prevention and Control (ECDC) showing a marked increase in Europe of multi-drug resistant Gram-negative bacteria resistant to the carbapenems – last-line antibiotics used to treat health care associated infections.
The Commission is therefore stepping up the fight against antimicrobial resistance (AMR) through the funding of 15 new research projects ( MEMO/13/996) and harmonized rules on the collection of data on AMR linked to animals and food ( MEMO/13/994).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze